Trinity Biotech director reports ADS option holdings
Trinity Biotech plc director Andrew Omidvar filed an initial Form 3 reporting holdings of ADS options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Trinity Biotech plc director Andrew Omidvar filed an initial Form 3 reporting holdings of ADS options. The options have an exercise price of $2.80 per ADS and expire on February 2, 2031. Multiple option tranches cover underlying ADS amounts of 7,292 and 2,917, with various future exercise dates extending into 2027.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Omidvar Andrew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
Holdings After Transaction:
ADS OPTIONS — 70,004 contracts (Direct)
Key Figures
Exercise price: $2.80 per ADS
Underlying ADS tranche: 7,292 ADSs
Underlying ADS tranche: 2,917 ADSs
+2 more
5 metrics
Exercise price
$2.80 per ADS
ADS options reported on Form 3
Underlying ADS tranche
7,292 ADSs
One set of ADS options at $2.80 exercise price
Underlying ADS tranche
2,917 ADSs
Additional ADS options at $2.80 exercise price
Option expiration
February 2, 2031
Expiration date for all reported ADS options
Holding entries
12 entries
Number of ADS option holding lines in the Form 3
Key Terms
Form 3, ADS options, exercise price, expiration date
4 terms
Form 3 regulatory
"filed an initial Form 3 reporting holdings of ADS options"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
ADS options financial
"reporting holdings of ADS options"
exercise price financial
"The options have an exercise price of $2.80 per ADS"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expire on February 2, 2031"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Trinity Biotech (TRIB) Form 3 for Andrew Omidvar show?
The Form 3 shows director Andrew Omidvar reporting holdings of Trinity Biotech ADS options. These derivative positions disclose his right to purchase ADSs at a fixed price rather than any recent share purchases or sales.
What is the exercise price of Andrew Omidvar’s Trinity Biotech ADS options?
Omdivar’s reported ADS options carry an exercise price of $2.80 per ADS. This means he can buy Trinity Biotech ADSs at $2.80 under these option awards, subject to their vesting and expiration terms.
When do Andrew Omidvar’s Trinity Biotech ADS options expire?
All reported ADS options held by Andrew Omidvar have an expiration date of February 2, 2031. After February 2, 2031, any unexercised options would lapse and no longer give the right to buy Trinity Biotech ADSs.
How many Trinity Biotech ADSs are covered by Omidvar’s $2.80 options?
The filing lists multiple tranches of ADS options, each tied to underlying ADS amounts of 7,292 and 2,917. These figures represent the number of Trinity Biotech ADSs that could be purchased under each respective option tranche.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates